Ipamorelin
Ipamorelin research comparisons at Saline Peptides
A selective hormone response earned this compound its reputation. I’d press that result on a further question: how much clinical benefit followed?
Human pharmacokinetics
The human ipamorelin study from 1999 has an appealingly definite result: a single growth-hormone pulse, peaking at about 40 minutes after intravenous administration. There were eight healthy male volunteers per dose level, and the terminal half-life was approximately two hours. Half-life describes how quickly the concentration falls; it cannot tell us how well someone sleeps or recovers from exercise.
Ipamorelin is a synthetic peptide made from five amino acids and activates the ghrelin receptor, GHS-R1a, to prompt growth-hormone release. Its founding experiments in rat pituitary cells, rats and conscious swine found potent GH release without significant ACTH or cortisol elevation, even at amounts more than 200-fold above the amount producing half the maximum GH response. This acute selectivity was a substantial pharmacological achievement.
A clean hormone result certainly appeals to me. The difficulty begins when that result is asked to stand in for a useful change in a person’s life.
Postoperative ileus clinical trial
The published Phase 2 trial in 114 adults after bowel resection tested recovery from postoperative ileus, the temporary slowing of the bowel after surgery. Median time to the first tolerated meal was 25.3 hours with ipamorelin and 32.6 hours with placebo. The trial missed its primary endpoint; p=0.15.
That numerical gap looks encouraging before its uncertainty comes into view. The missed endpoint settles my judgment of that trial, despite the attractive numerical gap. The experiment did not establish the benefit it set out to test.
Treatment-emergent adverse events occurred in 87.5% of the ipamorelin arm and 94.8% of the placebo arm. Both groups were recovering from surgery, which makes the comparator particularly valuable when interpreting those high percentages. The short perioperative study produced no ipamorelin-specific safety signal; long-term human safety remains unresolved.
Animal experiments
In adult female rats studied for 15 days, longitudinal bone growth measured 42 micrometers/day with vehicle and 44, 50 and 52 micrometers/day across the ipamorelin groups. The vehicle is the liquid carrying a study compound; giving it alone supplies a comparison. Total IGF-1, IGF-binding proteins and bone-turnover markers showed no measured change. That mismatch between a growing bone and an unchanged blood marker deserves my extra attention. Local effects and the pattern of GH release remain possible explanations.
The 2024 cisplatin experiment in ferrets supplies another useful separation: ipamorelin reduced chemotherapy-associated weight loss by approximately 24% on the last day of the delayed phase, yet had no anti-emetic effect in either the acute or delayed phase. Preserving weight and preventing vomiting came apart in these animals.
A 2026 narrative review also describes improved maximum muscle tetanic tension with CJC-1295 plus ipamorelin in a mouse model of glucocorticoid-induced muscle loss. The review calls for substantial human safety and efficacy research. None of these animal findings establishes a human recovery or body-composition benefit.
Safety; anecdotal reports
Community accounts describe deeper sleep, vivid dreams, quicker recovery and sometimes a leaner appearance; they also describe flushing, tingling, water retention, hunger, dizziness, fatigue and local irritation. These are anecdotal accounts, not clinical evidence. Many concern CJC-1295 combinations, and diet and training confound the body-composition stories. A report of a warm flush cannot establish a compound’s identity or its benefit.
My largest safety concern is the missing long-term human record. A study of a different ghrelin-receptor agonist in rats found myocardial degeneration and necrosis after chronic exposure. Ipamorelin was not the tested compound. The finding warrants scrutiny of this receptor class while leaving ipamorelin’s own chronic risk unmeasured.
Growth-hormone and IGF-1 biology also raises theoretical concern around active or recent malignancy; no ipamorelin-specific tumor-promotion trial resolves it. The net effects on glucose regulation and fluid retention need particular attention in the safety question. The acute selectivity experiments answer a narrower hormonal question than those concerns. Research-labelled material additionally lacks pharmaceutical assurance of identity, purity and sterility.
FDA status
Ipamorelin has never received FDA approval for any indication. On FDA’s page current as of April 22, 2026, ipamorelin acetate remains in Category 2 under the Section 503B interim policy and also appears among nominations withdrawn after Category 2 placement. A withdrawn nomination establishes neither permission to compound nor drug approval. FDA gives no withdrawal date.
The comparison page sets this research compound beside MOTS-c and retatrutide. A single ladder of desirability seems unhelpful to me: their trials ask different questions, and the gaps differ just as much as the findings.